Quantcast

Latest MDV3100 Stories

2009-04-08 13:51:06

U.S. medical scientists say two new drugs designed to treat metastatic prostate cancer have shown considerable promise in early clinical trials. The Howard Hughes Medical Institute researchers said of 30 men who received low doses of one the drugs in a multi-site phase I/II trial designed to evaluate safety, 22 showed a sustained decline in the level of prostate specific antigen in their blood. Phase III clinical trials are planned to evaluate the drug's effect on survival in a large group of...

2009-04-07 15:00:00

- Seminal Research on Prostate Cancer Resistance Leads to Development of MDV3100, Novel Drug Candidate - SAN FRANCISCO, April 7 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced publication of an article in the April 9, 2009, issue of Science Express, the online version of the journal Science, presenting the discovery and novel mechanism of action of MDV3100, the Company's androgen receptor antagonist drug candidate. MDV3100 has completed enrollment in a Phase 1-2...

2009-03-18 08:24:00

SAN FRANCISCO, March 18 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has received written permission from the U.S. Food and Drug Administration (FDA) to begin a pivotal Phase 3 trial of MDV3100, its novel androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (CRPC) who have failed docetaxel-based chemotherapy. The placebo-controlled, double-blind, multinational trial will enroll approximately 1,200 patients who...

2009-02-25 15:01:00

- MDV3100 Consistently Demonstrates Anti-Tumor Activity Across Doses and Endpoints in both Chemotherapy Naive and Post-Chemotherapy Patients - - Data To Be Presented at ASCO's 2009 Genitourinary Cancers Symposium - - Medivation to Host Conference Call and Webcast Presentation with Dr. Howard Scher Today at 4:30 p.m. Eastern Time - SAN FRANCISCO, Feb. 25 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new efficacy and safety data from an ongoing...

2008-12-17 07:00:00

SAN FRANCISCO, Dec. 17 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it has completed patient enrollment in a Phase 1-2 dose-escalation clinical trial of MDV3100, its novel androgen receptor antagonist, in castration-resistant prostate cancer patients, and that it will seek approval from the U.S. Food and Drug Administration (FDA) to advance to Phase 3 clinical trials next year. The open-label, U.S. Phase 1-2 study evaluated prostate cancer patients...

2008-10-24 09:00:07

Ariad Pharmaceuticals has reported encouraging preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. This data provide the scientific rationale for an ongoing Phase II clinical trial examining the same combination in patients with advanced prostate...

2008-10-23 09:00:39

Medivation, a biopharmaceutical company, has reported new data from an ongoing Phase I-II clinical trial demonstrating that the company's novel androgen receptor antagonist MDV3100 continues to show promising safety and efficacy results. The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings, circulating tumor cell (CTC) changes, and time on treatment....

2008-10-23 09:00:10

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer. This investigational study shows that the combination inhibits the growth of prostate cancer cell lines in various model systems. The data were presented at the EORTC-NCI-AACR (ENA) symposium on "Molecular Targets and Cancer Therapeutics" held in Geneva, Switzerland this...

2008-10-22 09:00:10

GENEVA and SAN FRANCISCO, Oct. 22 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced the presentation of new data from an ongoing Phase 1-2 clinical trial demonstrating that the Company's novel androgen receptor antagonist MDV3100 continues to show promising safety and efficacy results. The data showed encouraging and durable anti-tumor activity in the three expanded dose groups tested thus far, as measured by prostate specific antigen (PSA) declines, radiographic findings,...

2008-10-21 12:00:08

Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer. In collaboration with Merck, deforolimus is currently being studied in multiple clinical trials, both alone and in combination with other therapies, in patients with several different types of cancer. Under the...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related